Strategy & Corporate DevelopmentEvent: September 4, 2026
Labiotech.eu reports that Genentech collaborates with DualityBio to develop next-generation antibody-drug conjugates, with DualityBio receiving $45 million upfront and milestone payments.
Published
Signal category
Strategy & Corporate Development
Quote
“🇺🇸 Genentech collaborates with 🇨🇳 DualityBio to develop next-generation antibody-drug conjugates | DualityBio to receive $45 million upfront and is eligible to receive more than $1 billion in milestone payments”
— Labiotech.eu team
Company
Labiotech.eu
Europe’s premier digital media platform for the global biotech industry.
- Industry
- Online Audio and Video Media
- Location
- Berlin, DE
- Company size
- 20 employees
Labiotech.eu is Europe’s premier digital media platform for the global biotech industry. More than 130,000 monthly biopharma readers rely on Labiotech for insights into the latest innovations in biotechnology and our analysis of a dynamic industry. Subscribe today for access to our daily articles, in-depth content and extensive archive.
Founded 2014